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Myeloperoxidase, paraoxonase-1, and HDL
form a functional ternary complex
Ying Huang,1 Zhiping Wu,1 Meliana Riwanto,2,3 Shengqiang Gao,1 Bruce S. Levison,1 Xiaodong Gu,1
Xiaoming Fu,1 Matthew A. Wagner,1 Christian Besler,2,3 Gary Gerstenecker,4 Renliang Zhang,1
Xin-Min Li,1 Anthony J. DiDonato,1,5 Valentin Gogonea,1,4 W.H. Wilson Tang,1,6 Jonathan D. Smith,1,6
Edward F. Plow,6,7 Paul L. Fox,1 Diana M. Shih,8 Aldons J. Lusis,8 Edward A. Fisher,9
Joseph A. DiDonato,1 Ulf Landmesser,2,3 and Stanley L. Hazen1,6
1Department

of Cellular and Molecular Medicine, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio, USA. 2Cardiology,
Cardiovascular Center, University Hospital Zurich, and 3Cardiovascular Research, Institute of Physiology, and Center for Integrative Human Physiology,
University of Zurich, Zurich, Switzerland. 4Department of Chemistry, Cleveland State University, Cleveland, Ohio, USA. 5Department of Psychology,
John Carroll University, University Heights, Ohio, USA. 6Department of Cardiovascular Medicine and 7Department of Molecular Cardiology, Cleveland Clinic,
Cleveland, Ohio, USA. 8Department of Medicine/Division of Cardiology, BH-307 Center for the Health Sciences, UCLA, Los Angeles, California, USA.
9Department of Medicine, New York University, New York, New York, USA.

Myeloperoxidase (MPO) and paraoxonase 1 (PON1) are high-density lipoprotein–associated (HDL-associated) proteins mechanistically linked to inflammation, oxidant stress, and atherosclerosis. MPO is a source
of ROS during inflammation and can oxidize apolipoprotein A1 (APOA1) of HDL, impairing its atheroprotective functions. In contrast, PON1 fosters systemic antioxidant effects and promotes some of the atheroprotective properties attributed to HDL. Here, we demonstrate that MPO, PON1, and HDL bind to one another,
forming a ternary complex, wherein PON1 partially inhibits MPO activity, while MPO inactivates PON1.
MPO oxidizes PON1 on tyrosine 71 (Tyr71), a modified residue found in human atheroma that is critical for
HDL binding and PON1 function. Acute inflammation model studies with transgenic and knockout mice for
either PON1 or MPO confirmed that MPO and PON1 reciprocally modulate each other’s function in vivo.
Further structure and function studies identified critical contact sites between APOA1 within HDL, PON1,
and MPO, and proteomics studies of HDL recovered from acute coronary syndrome (ACS) subjects revealed
enhanced chlorotyrosine content, site-specific PON1 methionine oxidation, and reduced PON1 activity. HDL
thus serves as a scaffold upon which MPO and PON1 interact during inflammation, whereupon PON1 binding partially inhibits MPO activity, and MPO promotes site-specific oxidative modification and impairment
of PON1 and APOA1 function.
Introduction
Cholesterol efflux activity and reverse cholesterol transport are
regarded as the classic functions of high-density lipoprotein
(HDL). Yet increasing evidence shows that additional cardioprotective antioxidant and antiinflammatory functions of HDL exist
(1, 2). Isolated HDL can reduce LDL-associated cholesteryl ester
hydroperoxides, fatty acid hydroperoxides, and certain oxidized
phosphatidylcholine molecular species (3). Moreover, HDL facilitates numerous antiinflammatory activities (4–7). Interestingly,
reconstituted particles containing apolipoprotein A1 (APOA1),
the major structural protein within HDL, can recapitulate some
but not all of these activities (6–8). Thus, the antiinflammatory
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and antioxidant activities of HDL are thought to be mediated in
part by both APOA1 within the core lipoprotein particle and an
assortment of HDL-associated proteins.
Early proteomics studies of HDL provided the first glimpse into
the complexity of the HDL-associated proteome, revealing HDL as
a highly heterogeneous array of distinct particles that are equipped
with a broad assortment of HDL-associated proteins, including
not only previously recognized exchangeable apolipoproteins,
but also numerous additional proteins involved in hemostasis,
thrombosis, the immune and complement systems, growth factors, receptors, and hormone-associated proteins (9, 10). Subsequent studies both replicated these findings and extended them by
suggesting that the composition of HDL-associated proteins may
differ between subjects having clinically significant cardiovascular
disease compared with healthy controls (11–13). This raises the
possibility that alterations in HDL function may occur through
changes in HDL-associated proteins. Indeed, the contemporary
view holds that distinct HDL particle subpopulations exist, which
are composed of unique clusters of specific HDL-associated proteins that foster specific biological functions (12). For example,
HDL particles enriched in paraoxonase 1 (PON1), an atheroprotective protein (14), have been linked to the antioxidative, antiinflammatory, and lipid cargo–carrying functions of HDL (7, 12, 15). An
esterase/lipolactonase with unclear substrate(s) in vivo, PON1 has
been shown to help HDL prevent the accumulation of lipid peroxides in oxidized LDL, inactivate bioactive oxidized phospholipids,
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stimulate HDL-mediated eNOS-dependent NO production, and
enhance cholesterol efflux from cholesterol-laden macrophages
(7, 16–18). The participation of PON1 in HDL-related beneficial functions extends to in vivo studies as well, since PON1 KO
mice show enhanced susceptibility for developing atherosclerosis
(19) and, conversely, Pon1 transgenic (Tg) mice demonstrate both
protection from the development of atherosclerosis and reduced
systemic measures of oxidation (20). Moreover, recent human
studies show a striking correlation between multiple systemic
measures of oxidant stress and serum PON1 activity measures
(15), and reduced systemic PON1 activity heralds increased prospective risks for major adverse cardiac events in subjects (15, 21,
22). PON1 has thus emerged as an important mediator of many
antiinflammatory, antioxidant, and atheroprotective activities of
HDL. A role for an HDL-associated protein in modulating PON1
activity levels within a distinct HDL particle subpopulation has
not yet been reported.
Myeloperoxidase (MPO) is a leukocyte-derived heme protein
that, like PON1, both binds to HDL and is mechanistically linked
to oxidant stress and atherosclerosis (23–27). While typically
found at very low levels within the plasma of healthy individuals, substantially elevated levels may be observed in the plasma
or serum of those with acute coronary syndromes (ACS) and at
risk for major adverse cardiac events (28). An enzymatic source
of diffusible oxidant species, MPO promotes protein and lipid
oxidation at sites of inflammation, including within the atherosclerotic plaque–laden artery where the enzyme is enriched and
catalytically active (24, 29–32). Studies using neutrophils (PMN)
isolated from subjects with MPO deficiency (PMNMPO–) reveal that
MPO is also a major enzymatic catalyst for the initiation of lipid
peroxidation within serum or plasma (33), and studies employing
MPO KO mice confirm that the leukocyte enzyme plays a dominant role in lipid peroxidation and eicosanoid formation at sites
of acute inflammation (34). When released from activated leukocytes, MPO within both the circulation and within human atherosclerotic plaque binds to HDL, targeting the particle for oxidative
modification and functional inactivation (6, 23, 35). Site-specific
oxidation of APOA1 of HDL by MPO has been linked to impairment in cholesterol efflux and LCAT-activating activities of the
lipoprotein, inhibition in antiinflammatory and antiapoptotic
properties of HDL, and acquisition of proinflammatory gain-offunction activities (6, 23).
The processes that regulate MPO activity in vivo are unclear.
Our current understanding is that the availability of MPO is
regulated predominantly by the extent of leukocyte activation
and granule content secretion, and catalytic activity of released
MPO is governed in large part by hydrogen peroxide substrate
availability. Whether MPO activity is further modulated by
interaction with additional proteins, such as after binding to
the HDL particle or a specific HDL-associated protein, is not
known. Given the numerous mechanistic and opposing links
between MPO and PON1 with systemic measures of oxidant
stress, inflammation, and atherosclerotic risk, we hypothesized
that these two HDL-associated proteins may functionally interact and inhibit each other’s catalytic activity either on HDL or
outside of their association with HDL.
Results
MPO and PON1 bind to one another and reciprocally inhibit each
other’s activity. To test the hypothesis that HDL, PON1, and MPO
3816

modulate each other’s activity, we initially examined whether
immunoprecipitation studies were consistent with a potential complex being formed between HDL, MPO, and PON1 in
plasma. As expected, antibodies against APOA1 pulled down both
MPO and PON1 from plasma (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/
JCI67478DS1). Importantly, cross immunoprecipitation studies in plasma with antibodies against either MPO or PON1 were
also consistent with ternary complex formation involving HDL
(APOA1), MPO, and PON1, since immunoprecipitation with antibodies against either MPO or PON1 similarly pulled down the
other 2 components (Supplemental Figure 1). To more fully assess
the strength of the interactions between each component of a presumptive HDL-MPO-PON1 complex, plasmon resonance spectroscopy was performed to evaluate binding interactions between
each of the components. Remarkably, HDL, MPO, and PON1 each
bound to one another with high affinity, showing KD values in the
low nanomolar-to-picomolar range, depending on the interaction
examined (Supplemental Figure 2).
PON1 in plasma is present on a subset of HDL particles (estimated at approximately 1 of 8–10 HDL particles) (36). And
MPO is significantly less abundant than either PON1 or HDL in
plasma. Western blot analyses with MPO antibodies following
immunoprecipitation with either PON1 or APOA1 reveal that the
vast majority of MPO in plasma is bound to HDL and PON1, as
nominal detectable MPO remains in the supernatant following
immunoprecipitation with antibodies against APOA1 and PON1
(not shown). The above binding studies suggest that MPO, when
present within plasma or serum or within other bodily tissues or
fluids, may interact with APOA1 and PON1 in a subset of HDL
particles. The ability of MPO to oxidize APOA1 and alter HDL
function is well known (6, 23). Whether interactions between MPO
and PON1 might alter the function of each of these HDL-associated proteins, however, is unclear. We therefore next examined
whether MPO activity (using varying levels of H 2O2) impacted
PON1 activity within a complex matrix-like serum. Physiological levels of HDL (1 mg protein/ml) and PON1 (100 μg/ml) were
added to lipoprotein-deficient serum from a healthy volunteer in
which the MPO levels measured were nominal (<50 picomolar). In
the absence of additional MPO, increasing amounts of the MPO
substrate H2O2 had minimal effect on PON1 activity. In contrast,
upon the addition of pathophysiological levels of MPO (e.g., 5 nM),
a dose-dependent inhibition of PON1 catalytic activity was
observed with increasing levels of H2O2 (Figure 1A). The addition
of a large molar excess of methionine, a scavenger of hypochlorous
acid (HOCl) — the major oxidant formed from MPO in the presence of plasma levels of chloride — blocked the inhibitory effect
of MPO/H2O2 on PON1, in agreement with HOCl as the reactive
oxidant responsible for the loss of PON1 catalytic activity. Consistent with this, in a parallel study, HOCl was incrementally added
to lipoprotein-deficient serum supplemented with HDL and
PON1 in the absence of MPO. Again, a dose-dependent inhibition
of PON1 catalytic activity was observed (Figure 1A). Importantly,
comparisons between the MPO/H2O2/Cl– system (an enzymatic
source of HOCl) and HOCl at molar-equivalent doses demonstrated MPO to be a more potent inhibitor of PON1 activity at
every level of oxidant examined, consistent with MPO binding
to the HDL-PON1 complex within serum and the reactive HOCl
formed by MPO having a shorter diffusion distance (and hence,
less scavenging) before hitting the PON1 target (Figure 1A).
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ingly, the addition of HDL to MPO
resulted in a reproducible, modest
increase in MPO peroxidase activity;
however, the addition of PON1 in
the presence of HDL still resulted in
a reduction in MPO peroxidase activity by approximately 50% (Figure 1C).
To further explore the physiological
relevance of MPO-PON1 interaction,
additional studies were performed.
We previously used isolated human
neutrophils from normal and MPOdeficient subjects to show that neutrophil activation in plasma or serum
is a physiological mechanism for the
initiation of lipid peroxidation, such
as at sites of acute inflammation,
through a mechanism requiring
MPO (33). We therefore examined
the impact of PON1 on human neutrophil–dependent lipid peroxidation in serum as monitored by stable
isotope dilution liquid chromatography tandem mass spectrometry (LC/
MS/MS) quantification of oxidation
products of arachidonic (e.g., hydroxyeicosatetraenoic acid [HETEs]) and
linoleic acids (e.g., hydroxyoctadecadienoic acid [HODEs]). As expected,
the addition of neutrophils from
normal volunteers (PMN WT ) to
serum failed to promote lipid peroxidation under basal conditions, but
did so following neutrophil activation by the addition of phorbol ester
agonist (Figure 1D). As an additional
control to show that the lipid peroxFigure 1
idation monitored was attributable
MPO and PON1 inhibit each other’s activity in vitro. (A) PON1 (100 μg/ml) was incubated with either
to MPO release from the PMN, parHOCl or H2O2 and MPO (50 nM) in 50 mM Na[PO4] buffer (pH 7.0) supplemented with isolated human
HDL (1 mg/ml) and 100 mM NaCl at 37°C for 60 minutes. This was followed by quantification of paraox- allel studies using neutrophils isoonase activity relative to no oxidant exposures. Also shown are the effects of varying levels of H2O2 lated from an MPO-deficient subject
alone (i.e., no MPO added) or with the addition of the HOCl scavenger methionine (Met) (10-fold molar (PMNMPO–) were performed, demonexcess relative to oxidant) to the MPO/H2O2 system. (B) Effect of PON1 on peroxidase activity by TMB strating no formation of 9-HETE (a
assay of either MPO or HRP. (C) Effect by TMB assay of PON1 (650 nM), HDL (650 nM), or both on free radical–specific oxidation prodMPO (65 nM) peroxidase activity. (D and E) Human neutrophils isolated from healthy donors (PMNWT) uct of arachidonic acid) following
or MPO-deficient subjects (PMNMPO–) were incubated at 37°C in 50% serum for 1 hour in the absence
the addition of phorbol ester agonist,
or presence of phorbol 12-myristrate 13-acetate (PMA) and MPO or PON1, as indicated. Endogenous serum arachidonic acid (AA), linoleic acid (LA), 9-HODE, and 9-HETE were then quantified by but marked 9-HETE formation upon
stable isotope dilution LC/MS/MS as described in Methods. (F) PON1, MPO/H2O2, neither, or both the addition of catalytic levels of
were added to 50% serum, incubated at 37°C for 1 hour, and then AA, LA, or the indicated oxidation MPO to activated PMNMPO– (Figure
products were quantified as described in Methods. Data shown represent the mean ± SD of triplicate 1D). The addition of PON1 to serum
determinations. *P < 0.05; **P < 0.001. NA, no additions; oxFA, oxidized fatty acids.
in the presence of quiescent PMNWT
resulted in no change in 9-HODE or
9-HETE levels, but markedly attenWe next sought to test whether PON1 could influence MPO uated the incremental increases in lipid peroxidation products
catalytic activity. The addition of PON1 to MPO inhibited per- formed upon PMNWT stimulation (Figure 1E). In a parallel set of
oxidase activity by approximately 50% (Figure 1B). The effect of studies, the direct impact of PON1 on the extent of MPO-cataPON1 on MPO peroxidase activity was specific, since the replace- lyzed formation of multiple distinct molecular species of HETEs
ment of MPO with an alternative heme peroxidase, HRP (but and HODEs in serum was determined by stable isotope dilution
the same levels of H2O2 and chromophore substrate), showed LC/MS/MS. Again, the addition of PON1 markedly attenuated
no effect of PON1 on peroxidase activity (Figure 1B). Interest- MPO-dependent initiation of lipid peroxidation and formation of
The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 9   September 2013
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Figure 2
MPO and PON1 inhibit each other’s activity in vivo. (A) PON1 KO,
WT, or PON1 Tg animals were injected i.p. with normal saline (Bl) or
thioglycollate broth (T). Twenty-four hours later, peritoneal lavages
were performed. Where indicated, mice were injected with zymosan (Z)
24 hours after thioglycollate, and peritoneal lavage was performed
4 hours later. Chlorotyrosine (ClTyr) content (normalized to the precursor amino acid tyrosine [Tyr]) in soluble proteins recovered from
peritoneal lavage was determined by stable isotope dilution LC/MS/MS
analysis. (B) MPO KO, WT, or MPO Tg animals were injected i.p. with
normal saline or zymosan (Z). After 72 hours of subacute peritonitis,
serum was isolated and paraoxonase activity was measured.

the various HETEs and HODEs from endogenous lipids in serum
(Figure 1F). Collectively, these results indicate that within a physiological matrix like plasma or serum, MPO and PON1 can interact
with one another and modulate each other’s activity.
MPO and PON1 influence each other’s activity in vivo. To further
extend our observations of the reciprocal inhibitory effects of
MPO and PON1 on each other’s activity from an in vitro (ex vivo)
to an in vivo setting, further studies were performed using mice
genetically engineered to lack (KO) or overexpress (Tg) either
MPO or PON1. We chose a simple and well-characterized peritonitis model of acute inflammation for these studies, since we
have previously shown that MPO serves as a major enzymatic
catalyst for both protein and lipid oxidation within the model
(31, 34). To examine the impact of PON1 on MPO activity, we
quantified protein-bound 3-chlorotyrosine (ClTyr), a specific
molecular fingerprint for MPO-catalyzed protein oxidation (29,
31), in peritoneal proteins recovered from PON1 KO, WT, and
PON1 Tg mice following the recruitment of leukocytes to the
peritoneal cavity with thioglycolate and subsequent activation by
i.p. injection of yeast cell wall protein carbohydrate components
(zymosan). Compared with WT, the PON1 KO mice demonstrated a significant (P = 0.02) approximately 50% increase in
protein-bound ClTyr content within recovered peritoneal lavage
fluid proteins (Figure 2A). A dose-dependent effect of increased
PON1 leading to reduced MPO activity, as monitored by ClTyr
formation, was further supported by demonstration of an
approximately 50% reduction (P < 0.01) in peritoneal lavage protein ClTyr content in PON1 Tg mice relative to the WT controls
(Figure 2A). Thus, PON1 shows a dose-dependent inhibitory
3818

effect on the production of the MPO-specific oxidation product,
ClTyr, in an acute inflammation model.
In a parallel set of studies, we determined the impact of genetic
alterations in MPO levels on systemic PON1 activity measured
during inflammation. Here, serum paraoxonase activity was
measured in a subacute peritonitis model following i.p. zymosan
injection. In WT mice, chronic inflammation (72 hours) induced
by the i.p. zymosan resulted in a significant (P < 0.05) 30% reduction in serum paraoxonase activity (Figure 2B). The initiation of
peritonitis in the human MPO Tg mouse revealed an even more
pronounced inhibition in systemic paraoxonase activity (55%,
P < 0.001), whereas the induction of peritonitis under comparable
conditions within the MPO KO mouse failed to change systemic
PON1 activity levels (Figure 2B). Importantly, the examination
of circulating PON1 concentrations shows similar levels between
MPO KO and MPO Tg mice (Supplemental Figure 3). Thus,
changes observed in PON1 activity within serum are consistent
with the inhibition of catalytic activity (specific activity) of the
protein via an MPO-dependent process.
Hydrogen deuterium exchange mass spectrometry and mutagenesis
studies reveal functional interaction sites on APOA1 of HDL and PON1.
We next sought to identify sites of contact between PON1 and
APOA1 of reconstituted nascent HDL (nHDL). Hydrogen-deuterium exchange mass spectrometry (HDX) is a powerful tool for
identifying protein-protein interaction sites and was used to identify the MPO binding site on APOA1 of nHDL (23). We therefore
used HDX to interrogate the potential site(s) on APOA1 within
nHDL involved in PON1 interactions. Examination of amide
proton deuterium incorporation factors in peptic peptides generated from APOA1 of nHDL in the absence or presence of PON1
revealed 2 regions of the APOA1 polypeptide chain with a significant (>10%) reduction in deuterium incorporation factor in the
presence of PON1. Multiple overlapping peptic peptides helped
to define the regions showing a reduction in deuterium exchange
in the presence of PON1, Leu38-Leu46 (termed P1, located at the
boundary between the APOA1 N-terminal and helix 1) and Thr202Arg215 (termed P2, located at the boundary between helix 8 [7 residues] and helix 9 [7 residues]) (Figure 3, A and B). Examination
of the locations of these regions on the recently proposed double
superhelix model of nHDL developed using a combination of contrast variation, small-angle neutron scattering, HDX, and chemical
cross-linking/mass spectrometric studies (37) revealed that P1 and
P2 are predicted to reside directly opposite to one another on the 2
antiparallel APOA1 chains (Figure 3C). Moreover, they are in close
spatial proximity to the site of interaction previously identified
between MPO and APOA1 in nHDL (APOA1 residues 190–203)
(23). Of note, the identified peptide regions P1 and P2 of APOA1
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Figure 3
PON1 interaction sites on APOA1 within nHDL
revealed by HDX MS. (A) Plot indicating the percentage of deuterium incorporation of exchangeable protons within individual peptic peptides of
APOA1 in nHDL in the absence (black bars) versus presence (white bars) of PON1. **P < 0.05.
(B) Plot showing percentage change in deuterium incorporation of individual peptic peptides
of APOA1 in nHDL in the absence or presence
of PON1. Two regions of APOA1 demonstrate a
significant reduction in deuterium incorporation in
the presence or absence of PON1/P1 (L38GKQLNLKL46) and P2 (S201TLSEKAK208). Dotted line
marks the 10% reduction in deuterium incorporation. (C) Illustration of PON1 interaction domains
P1 and P2 on APOA1 within the double superhelix model of nHDL. The two APOA1 molecules
are aligned in a head-to-tail antiparallel arrangement using a helix 5/helix 5 registry. N-termini are
shown in dark red/blue, and C-termini are shown
in light red/blue. PON1 interaction sites on nHDL
(P1, blue; P2, light red).

are located directly opposite or adjacent to one another on the
antiparallel APOA1 chains in every reported HDL model available
as a Protein Data Bank (PDB) file (37–45).
To examine the functional significance of the APOA1 sequences
identified as potential contact sites between nHDL and PON1,
site-directed mutant forms of APOA1 were generated, whereby
the WT sequences within P1 (L38GKQLNLKL46) and P2 (S201TLSEKAK208) were altered, removing potential hydrogen bond and
ionic interaction sites (P1 mut = L 38GEALALEL 46 and P2 mut =
S201ALAAEAE208) (Figure 3B). Initial control studies using recombinant APOA1 mutant forms generated with either the P1mut or
P2mut sequences revealed that both were functionally active and
indistinguishable from human APOA1 with respect to overall
structure as monitored by circular dichroism (Supplemental
Figure 4A) and ABCA1-dependent efflux activity from cholesterol-loaded RAW cells (Supplemental Figure 5A). Similarly, nHDL
produced using recombinant human APOA1 (WT) versus either
the P1mut- or P2mut-containing APOA1 forms showed similar
overall structure (Supplemental Figure 4B) and comparable total
cholesterol efflux activity with cholesterol-loaded RAW cells (Supplemental Figure 5B). Surface plasmon resonance spectroscopy
was also performed to evaluate the binding interaction changes
between PON1 and nHDL produced using recombinant human
APOA1 (WT) versus either the P1mut- or P2mut-containing APOA1
mutant forms. KD values of interaction between PON1 and nHDL

formed with either the P1mut or P2mut recombinant APOA1 forms
were decreased by 1.6-fold and 2.6-fold, respectively, compared
with the observed KD values for interaction of PON1 with nHDL
formed with recombinant human (WT) APOA1 (Supplemental
Figure 6). We therefore next examined whether P1 or P2 sequences
in APOA1 were involved in PON1 interactions. Purified PON1 is
more thermally labile in the absence of HDL and can lose catalytic
activity with prolonged incubation at 37°C (Figure 4A). However,
in the presence of either lipid-free APOA1 (Figure 4A, green curve),
phospholipid vesicles (Figure 4B, purple curve), or nHDL (Figure
4B, green curve), PON1 activity is both stimulated and stabilized
over time, consistent with binding to both lipid and protein components of reconstituted nHDL. Remarkably, incubation of PON1
with either of the P1mut- or P2mut-containing recombinant APOA1
forms or the reconstituted nHDL generated using these mutant
APOA1 forms showed intermediate capacity to bind, stimulate,
and stabilize PON1 activity during prolonged incubations at 37°C
(Figure 4, A and B). The intermediate phenotypes (protection
from thermal denaturation) observed with nHDL formed using
the mutant P1 or P2 sequences is consistent with these regions on
APOA1 serving a functional role in partially supporting the HDLPON1 interaction. In another series of experiments, we sought to
determine whether the strength of the HDL-PON1 binary complex influences MPO activity. Of note, while the binary complex
formed by PON1 with nHDL that had been formed using WT
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Figure 4
Demonstration that APOA1 P1 and P2 regions are functionally important in the HDL-PON1-MPO ternary complex. (A) APOA1 harboring mutations within P1 or P2 region (versus WT) were incubated with PON1 at 37°C for the indicated times, and then paraoxonase activity was determined. Results were normalized (100%) to PON1 activity measured with no addition (NA) at t = 0. (B) PON1 was incubated with reconstituted
HDL (rHDL; 100:10:1, OPC/cholesterol/APOA1, mol/mol/mol) using the indicated APOA1 forms (WT versus P1 versus P2 mutants) or small
unilamellar vesicles (SUV) composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) (16:0, 18:1 phosphatidylcholine [PC]) for the
indicated times, and then paraoxonase activity was measured. Results were normalized (100%) to PON1 activity measured with no addition at
t = 0. (C) TMB assay showed the effect of varying levels of the binary complex composed of PON1 and the indicated rHDL (made with WT versus
P1 versus the P2 APOA1 mutant) on MPO activity. All results represent the mean ± SD from at least 3 independent experiments. In A and B, the
differences between WT and mutants at the 3-hour point were significant (APOA1 WT versus APOA1 P1, P < 0.05; APOA1 WT versus APOA1
P2, P < 0.05). In C, the difference between WT and mutants at a molar ratio of rHDL/PON1 to MPO of 20 or greater were significant (rHDL WT
versus rHDL P1, P < 0.05; rHDL WT versus rHDL P2, P < 0.05).

recombinant human APOA1 inhibited MPO activity by approximately 50%, the PON1 complex formed with nHDL prepared with
either the P1 or P2 APOA1 mutant demonstrated a reduced ability
to inhibit MPO activity (Figure 4C).
PON1 Tyr71 is a functionally important site for HDL interaction and a
target for MPO-catalyzed oxidation in human atherosclerotic plaque. To
investigate sites on PON1 that may participate in HDL interactions, we generated reconstituted nHDL, incorporating instead
of cholesterol, a synthetic photoactivatable cholesterol analog
containing a diazirine moiety at C6 of the sterol, as described in
Methods (Figure 5A). Following exposure to UV light, the carbene
diradical formed by N2 elimination from the diazirine has an
exceedingly short half-life, with diffusion-limited reactivity with
water (46). Thus, in the presence of an HDL binding partner such
as PON1, UV light exposure is anticipated to produce a covalent
adduct only with PON1 residues in close enough spatial proximity to the lipid phase of nHDL to exclude water (Figure 5A).
Following coincubation of PON1 and nHDL and brief UV light
exposure, mass spectrometry identified only one residue within
PON1 that produced a cholestanyl adduct: Tyr 71 (Figure 5, A
and B). Remarkably, separate in vitro studies incubating HDLPON1 (1:1, mol/mol) complexes with either the MPO/H 2O2/
Cl– system or the MPO/H2O2/NO2– system at low oxidant levels
(H2O2/APOA1, 10:1, mol/mol) identified in a reproducibly similar manner Tyr71 of PON1 as a preferred site of MPO-catalyzed
oxidative modification, whereby Tyr71 of PON1 was detected as
either a 3-chlorotyrosine or 3-nitrotyrosine adduct within tryptic peptides by proteomics studies (Supplemental Figures 7, A
and B). The crystal structure of PON1 was recently reported (47,
48), and PON1 Tyr71 sits near the putative interfacial region of
the hypothetical HDL binding domain (Figure 5C), suggesting
both that Tyr71 of PON1 may support HDL interaction, and that
MPO-dependent site-specific oxidative modification of PON1 at
Tyr71 may impair PON1 function in vivo. The potential physiological relevance of PON1 Tyr71 oxidation by MPO was further
3820

supported by proteomics studies of PON1 recovered from human
atherosclerotic plaque, in which ClTyr71 was directly visualized
on PON1 tryptic peptides (Supplemental Figure 8). These results
demonstrate that within the proinflammatory environment of
the human atherosclerotic plaque where site-specific oxidation of
APOA1 through both nitration and chlorination has been shown
to occur by MPO (6, 23, 35), the HDL-associated protein PON1
too is oxidized by the heme protein.
In an additional series of studies, we sought to further explore
the potential functional significance of posttranslational oxidative
modification of Tyr71 of PON1. Site-directed mutagenesis studies
of recombinant human PON1 were performed, whereby tyrosine
was converted to multiple alternative amino acids (alanine, aspartic acid, or lysine). Each of the recombinant mutant PON1 forms
and recombinant human PON1 were next individually incubated
with nHDL (1:1, HDL-PON1, mol/mol) at 37°C, and then residual PON1 catalytic activity was quantified. Functional analyses of
recombinant human PON1 versus the site-directed mutant forms
of PON1 (aka Tyr71Ala, Tyr71Asp, or Tyr71Lys) showed that in each
case, the mutant PON1 form had markedly reduced catalytic
activity (Figure 5D). Collectively, these studies show that Tyr71 of
PON1 is both a site-specific target for MPO-catalyzed oxidation in
human atherosclerotic plaque and a functionally important residue for HDL interaction and preservation of PON1 activity.
HDL-bound PON1 is a selective target for MPO-catalyzed oxidation
and functional impairment during cardiovascular disease. We next
sought to further examine the functional and potential clinical
significance of the interaction between MPO and PON1 within
the HDL-PON1-MPO ternary complex during cardiovascular disease. Subjects (n = 26) presenting for diagnostic coronary angiography at the time of ACS were consented, and blood was drawn
for systemic PON1 activity determination and HDL isolation and
chlorotyrosine content determination. In parallel, age-, sex-, and
blood pressure–matched healthy nondiabetic control subjects
(n = 26) were consented and similarly examined. Baseline charac-
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Figure 5
PON1 Tyr71 is a functionally important site
for HDL interaction and a target for MPOcatalyzed oxidation in human atherosclerotic
plaque. (A) Schematic illustration of photocholestanyl-labeled PON1 tyrosyl residue.
(B) Reconstituted HDL formed using POPC/
photocholesterol/APOA1 (100:10:1) was
incubated with PON1 and exposed to UV
light as described in Methods. Proteomics
studies revealed the photocholestanyl adduct
of PON1 Tyr71 [Y(ch)] as a site on PON1
that directly interacts with cholesterol as
described in Methods. m/z, mass-to-charge
ratio. (C) PON1 crystal structure with superimposed location of Tyr71 (red) and hypothetical HDL binding surface based on hydrophobicity analysis. (D) Recombinant human
WT PON1 versus the indicated PON1 Tyr71
site–specific mutants were generated, isolated, incubated with HDL, and then paraoxonase activity was determined as described
in Methods. Results represent the mean ± SD
from at least 3 independent experiments.

teristics and laboratory analyses within the case-control cohort are
shown in Supplemental Table 1, and Figure 6A shows a scatter plot
demonstrating the relationship between systemic PON1 activity
measured within each group and protein-bound 3-chlorotyrosine
content in the isolated HDL as determined by stable isotope dilution LC/MS/MS. Of note, examination of the relationship between
the chlorotyrosine content of HDL and systemic PON1 activity
showed a significant inverse association within the combined ACS
plus healthy control cohort (r = –0.54, P < 0.001). Further, despite
substantial overlap, systemic PON1 activity was significantly
(P < 0.05) reduced within the ACS cohort compared with the
healthy controls (Figure 6A), and protein-bound chlorotyrosine
content of isolated HDL, a specific molecular marker of MPOcatalyzed oxidation (29, 31), was also elevated (P < 0.01) within the
ACS cohort relative to the healthy controls (Figure 6A). The small
size of this study, however, prevents examination of the impact of
comorbidities on these associations.
In a final series of studies, we further investigated the oxidative
inactivation of PON1 during ACS. A separate case-control study
was performed for more detailed proteomics analyses involving
an independent cohort of ACS subjects (n = 10) and age-, sex-, and
blood pressure–matched healthy nondiabetic controls (n = 10).
Baseline characteristics and laboratory analyses within this independent case-control cohort are shown in Supplemental Table 2.
HDL was isolated from subjects, and then PON1 tryptic peptides
were examined by proteomics. Methionine residues are highly susceptible to oxidation and conversion into methionine sulfoxide.
We therefore quantified site-specific methionine residue oxidation within PON1 recovered from the isolated HDL in both ACS
and control subjects, as described in Methods. Multiple methionine residues within PON1 were detected, and 3 (Met88, Met55, and

Met12) were reproducibly observed, permitting quantification of
both parent (unmodified) and oxidized forms (exemplary spectra shown in Supplemental Figures 9 and 10) within all samples.
Interestingly, the levels of oxidized Met88 were significantly elevated (P < 0.05) within the PON1 recovered from ACS subjects
relative to controls (Figure 6B and Supplemental Figure 11),
indicating that PON1 undergoes site-specific oxidative modification during ACS. To assess whether methionine oxidation may
have functional significance for PON1 activity, we examined the
impact of methionine sulfoxide reductase incubation with PON1
that had previously been partially functionally inactivated by
exposure to the MPO/H2O2/Cl– system. Remarkably, incubation
of oxidized PON1 with methionine sulfoxide reductase significantly reversed a portion of the PON1 inactivation induced by
MPO-generated oxidants (Figure 6C).
Discussion
MPO release from activated leukocytes, binding to HDL, and
targeting of APOA1 for oxidative modification and functional
inactivation of the particle are phenomena recognized to occur
during inflammation and have been linked to the generation of
“dysfunctional” forms of HDL (6, 23, 24, 35, 49–51). Moreover,
a reduction in systemic PON1 activity during cardiovascular disease in mice and humans has been reported and has been linked
to the loss of antiinflammatory properties of HDL isolated from
ACS subjects (7, 15, 19). Finally, a role for MPO in the initiation
of lipid peroxidation in vivo (33, 34) and a reciprocal association
between PON1 activity and systemic measures of oxidant stress in
mice and humans are well documented under a variety of inflammatory conditions (15, 19, 20). That these functions of MPO and
PON1, both HDL-associated proteins, should be mechanistically
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Figure 6
Methionine oxidation plays a role in PON1 activity and stability. (A)
Inverse correlation between systemic PON1 activity and protein content of ClTyr-isolated HDL from ACS (black ovals; n = 26) and healthy
nondiabetic control subjects (white ovals; n = 26) from case-control
cohort 1 (see Supplemental Table 1). P value shown is for the Spearman’s rank correlation between PON1 activity level and HDL ClTyr
content among both control and ACS subjects. (B) Quantification of
site-specific methionine oxidation (methionine sulfoxide) within PON1
recovered from isolated HDL from ACS (n = 10) and healthy nondiabetic control subjects (n = 10) enrolled in case-control cohort 2 (Supplemental Table 2). Results shown are expressed as the peak ratio of
peptide harboring the indicated methionine sulfoxide residue or parent
(methionine-harboring) peptide relative to the reference peptide, as
described in Methods. (C) Isolated human HDL from a healthy donor
was incubated with the MPO/H2O2/Cl– system (oxHDL), and then the
effect of exposure to either methionine sulfoxide reductase (+MSR) or
vehicle control (–MSR) on PON1 activity was determined as described
in Methods. PON1 activity is expressed relative to paraoxonase activity
measured in HDL prior to exposure to the MPO/H2O2/Cl– system. Data
are the mean ± SD of triplicate determinations.

linked has not yet been examined. We believe that the present studies demonstrate for the first time both the reciprocal biochemical
functional relationship between MPO and PON1 activities as they
relate to systemic measures of oxidant stress and HDL function
and a structural basis accounting for the linkage of these phenomena — namely, that MPO, PON1, and HDL can form a ternary
complex whereupon each member of the complex interacts with
and functionally impacts the other’s activity in vivo. Thus, the
present studies show that like APOA1 (6, 23), the HDL-associated
protein PON1 may be targeted for oxidative modification and
functional inactivation by MPO in vivo, as observed using both
animal models of inflammation and in human clinical studies of
the acute inflammatory condition, ACS.
A model of a hypothetical ternary complex of MPO and PON1
bound to nHDL is illustrated in Figure 7 and can help to provide a structural rationale for the observed reciprocal regulatory
behavior among MPO, PON1, and HDL within the context of the
present studies and prior reported observations. The model is
not intended to represent a true all-atom structure, but rather is
an illustration providing a structural and mechanistic rationale
upon which a variety of biophysical and functional observations
can be explained. The model shown is based on the known crystal
structures of PON1 (48) and MPO (52) and represents a model of
HDL based on small-angle neutron scattering and HDX studies
of nHDL (37), prior reported sites of MPO-catalyzed oxidative
modification to APOA1 in HDL (23, 35, 49, 53), previously identified MPO-APOA1 interaction sites based on hydrogen/deuterium (H/D) exchange and functional studies (23), and newly
discovered sites of oxidation or interaction among the various
participants in the ternary complex from the present studies. Of
note, while the discussions of the ternary complex below are based
on the double superhelix model of nHDL (37) as the scaffolding
upon which MPO and PON1 are bound (Figure 7), alternative
models for the HDL-PON1-MPO ternary complex using either a
discoidal HDL (e.g., solar flare model) (ref. 43 and Supplemental
3822

Figure 12) or a spherical HDL model (ref. 44 and Supplemental
Figure 13) as the lipoprotein scaffolding show similar conceptual findings in terms of distance constraints between identified
contact sites within the complex and provide a rationale for sites
of MPO-catalyzed oxidation observed on APOA1 and PON1
in vitro and in vivo. Because the double-belt discoidal model
of HDL contains a truncated APOA1 (residues 44–243), which
misses 6 residues from the P1 binding site, it was not included.
The model of the ternary complex is based on the nonoverlapping but directly adjacent sites on APOA1 of nHDL to which the
interaction sites with MPO and PON1 map. The close proximity
of these HDL-associated proteins on the HDL scaffold, coupled
with the high affinity MPO and PON1 show for one another,
suggest that there may be some direct interaction between
PON1 and MPO when they are both associated with HDL, and
this appears to be at the origin of the mutual activity modulation. This observation is supported by the data in Figure 1C,
which clearly indicate that MPO activity, when it associates with
PON1 either alone or on an HDL particle, is about half of its
activity compared with the absence of PON1.
PON1 is an HDL-associated enzyme under consideration as a
potential therapeutic for cardiovascular disease. While studies
in both mice (19, 20) and humans (15) support an antioxidant
function for the protein, the precise mechanism(s) through which
PON1 promotes its systemic antiinflammatory and antioxidant
effects are not well defined. Moreover, systemic PON1 activity levels can vary over a very broad range (orders of magnitude), while
PON1 mass shows less variation, with PON1 abundance in the
circulation being approximately one-tenth that of HDL particles (36). The mechanism(s) contributing to the wide variation
in systemic PON1 activity observed between subjects are not well
known, but early in vitro studies established the sensitivity of
PON1 to chemical oxidants (54). The present studies show that
under inflammatory conditions, MPO-mediated oxidative inactivation contributes to modulation of PON1 in vivo. It should
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Figure 7
Structural model of a hypothetical ternary complex of MPO and PON1
bound to nHDL. Illustration of an HDL-MPO-PON1 ternary complex
composed of the double superhelix model of nHDL and the crystal
structures of MPO and PON1 bound to one another with identified protein-protein interaction sites. The two predominantly α helical APOA1
chains in nHDL are aligned in a head-to-tail antiparallel arrangement.
N-termini are shown in dark red/blue, and C-termini are shown in light
red/blue. Phospholipids in the lipid core of nHDL are depicted in semitransparent green. PON1 binding sites on APOA1 shown are P1 (L38L46, solid blue) and P2 (S201-K208, solid light red). Adjacent MPO binding
site on APOA1 (residues A190-L203, filled light blue) is also depicted.
Site-specific oxidative modifications found in PON1 recovered from isolated HDL from either atherosclerotic lesions or ACS plasma include
Tyr71 (red) and Met55 and Met88 (both green). Met12 of PON1 is not
shown because the N terminus (16 amino acids) of PON1 was not
resolved in the PON1 crystal structure reported. Location of the openings to the two heme pockets on the MPO homodimer are predicted
to be in close spatial proximity to the site-specific oxidative modifications reported in APOA1 recovered from human atherosclerotic plaque,
Tyr166, and Tyr192 (solid black). Also shown are the “solar flare” regions of
APOA1, presumed LCAT interaction sites (solid yellow).

be noted that functional polymorphisms can also contribute to
variations in PON1 activity, but the magnitude of alterations are
relatively modest compared with the breadth of PON1 activity
levels observed in the systemic circulation (15, 55).
Despite the interest in PON1 and HDL as potential therapeutic
agents, the structural basis of the PON1-HDL interface has not
yet been defined. Our studies show that PON1 binding to HDL is
important for the maintenance of PON1 activity, with both lipid
and protein components of HDL supporting PON1 interaction
(Figure 4). Further, using a combination of novel biophysical
approaches, coupled with site-directed mutagenesis and subsequent functional studies, both Tyr71 of PON1 and the APOA1
sequences P1 (L38GKQLNLKL46) and P2 (S201TLSEKAK208) were
identified as critical residues in supporting HDL-PON1 interaction (Figures 3–6). PON1 Tyr71 was unambiguously identified as
a contact site with the lipid phase of HDL through the formation of a cholestanyl adduct using a reconstituted nHDL particle generated with a novel photoactivatable cholesterol analog
(Figure 5). The carbene diradical formed on the cholesterol analog following UV irradiation reacts at a near-diffusion-limited
rate with H2O, indicating that the interaction between the HDL
lipid phase and PON1 Tyr71 is sufficiently tight to exclude water,
and suggesting that the phenol moiety of Tyr71 extends into the
lipid phase upon HDL binding (Figure 8). It is remarkable that
recent crystallographic studies of PON1 in a ligand-bound form
identify PON1 Tyr71 as a critical residue that undergoes conformational change upon ligand binding and plays an important
role in a hydrogen bond network near the active site (Figure 8
and ref. 48). Our studies confirm the functional significance of

PON1 Tyr71 for HDL interaction through site-directed mutagenesis, since multiple PON1 mutants lacking Tyr 71 demonstrated
reduced HDL binding, thermal stability, and enzymatic activity
(Figures 5 and 6). Finally, the in vivo significance of this residue
is further suggested both by the demonstration that it is targeted
for MPO-catalyzed nitration and chlorination in model systems
under physiological levels of oxidant (Supplemental Figure 7)
and by the detection of PON1 3-chloroTyr71, a specific posttranslational modification formed by MPO in vivo, in PON1 recovered
from human atherosclerotic plaque (Supplemental Figure 8).
Importantly, examination of the crystal structure of PON1 indicates that posttranslational modification of the phenolic ring of
Tyr71 with a bulky substituent (e.g., NO2, Cl) will also interfere
sterically with the active site cavity walls and prevent Tyr71 from
forming a hydrogen bond with PON1 Asp183 (Figure 8), a critical residue that modulates access to the PON1 active site (48).
While the site of PON1 interaction with HDL was previously
unknown, the recent crystal structures reported for both free and
ligand-bound forms of PON1 suggest a possible lipid interfacial
binding surface based on predicted hydrophobicity characteristics of the protein (47, 48). It is notable that PON1 Tyr71 is structurally positioned near the hypothesized lipid-binding domain
within PON1 (Figure 5).
The present studies also help explain, in part, the specificity of
PON1 for interaction with HDL over alternative hydrophobic surfaces and lipoproteins, since specific docking sequences on APOA1
were also identified, showing functional importance in HDLPON1 interaction. HDX mass spectrometric studies revealed that
2 APOA1 regions (L38-L46 and S201-K208) display substantial reduc-
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Figure 8
Role of PON1 Tyr71 in HDL binding and catalysis. (A) Illustration indicating how Tyr71 of PON1 may interact with the cholesteryl group (orange)
of nHDL. PON1 crystal structure (PDB ID: 1V04) (purple) is shown
docking with the lipid phase of nHDL (POPC molecules are shown as
green lines, with the nitrogen atom of the choline group represented
by blue spheres), and Tyr71 (red) protrudes into the lipid phase, interacting with cholesterol. (B) Illustration comparing the conformation of
PON1 Tyr71 in the “closed” and “open” conformations of PON1 recently
reported by Tawfik and colleagues (48). The presumed “lid” domain
(K70-K81, cyan) in PON1 that seems to control access to the PON1
active site was resolved in the PON1 crystal structure with a lactone
analog bound to the active site (PDB ID: 3SRG; closed conformation)
only. If Tyr71 is nitrated, the bulky NO2 group interferes sterically with
some of the residues (H184, F222, F292) (purple) in the active site walls.
The halide Cl has an even larger van der Waals radius and would show
similar steric interference.

tions in deuterium incorporation at the amide proton in the presence versus absence of PON1, suggesting within the nHDL particle
that APOA1 binding to PON1 in these regions is tight enough to
partially exclude D2O (Figure 3). It should be noted, however, that
an alternative explanation for the H/D exchange data might be
that upon PON1 binding, APOA1 within HDL undergoes conformational changes that reduce amide proton exchange rates at
these residues. Mutagenesis studies, however, were also consistent
with the findings that these regions on APOA1 play a direct role in
PON1-HDL interaction, since these studies confirmed that both
P1 and P2 sequences are functionally important in PON1 binding
to HDL and in the maintenance of PON1 activity (Figures 3 and 4).
These APOA1 residues, however, do not appear to be critical for
either HDL formation or cholesterol efflux function (Supplemental Figures 4 and 5). Notably, what was found upon examination
of the anatomic location of the two APOA1 regions (P1 and P2)
on nHDL that help support binding to PON1 provides a logical
explanation for why these two apparently distant regions on the
APOA1 polypeptide chain support PON1 interaction — they are
predicted to be directly adjacent to one another on the two antiparallel APOA1 chains within HDL (Figures 3 and 7, and Supplemental Figures 12 and 13).
Perhaps one of the more remarkable findings in the present
studies is the previously unrecognized reciprocal functional interaction between MPO and PON1. In vitro studies with both isolated MPO and PON1 in serum or activated neutrophils from normal and MPO-deficient subjects demonstrate reciprocal effects
on PON1 and MPO activity within serum (Figure 1), and studies
with PON1 KO and Tg mice or MPO KO or Tg mice confirmed
the dose-dependent reciprocal effects of each protein on the
other’s enzymatic activity in vivo during inflammation (Figure 2).
Finally, the H/D exchange studies demonstrate that the site on
APOA1 supporting PON1 binding is in close spatial proximity to
the previously identified MPO binding site on APOA1 of nHDL
(23), and proteomics studies on PON1 reveal that Tyr71, along
3824

with multiple PON1 methionine residues (e.g., M55 and M88),
are predicted to be in close spatial proximity to 1 of the 2 heme
pockets of MPO (Figure 7). Indeed, we hypothesize that the structural rationale for PON1-dependent inhibition in MPO activity
observed in vitro, which was approximately 50% of total activity
(Figure 1), likely arises because PON1 binding to MPO may block
substrate access to 1 of the 2 heme pocket active sites on the MPO
homodimer (Figure 7). It should be noted that the precise interaction sites on MPO for PON1 binding, however, remain to be
determined. The protease-resistant nature of MPO, coupled with
its high degree of glycation, hinders structural elucidation of the
residue(s) on MPO where it interacts with PON1, even though
the binding interaction shows a KD in the low nanomolar range
and is tight enough to permit cross immunoprecipitation studies
to pull down MPO or PON1 along with APOA1 with antibodies
against the alternative partners in the ternary complex (Supplemental Figures 1 and 2).
Prior reported studies demonstrating the selective enrichment of
NO2Tyr and ClTyr within APOA1 recovered from serum or within
human atherosclerotic vessels suggest a possible (patho)physiologic association between APOA1 and MPO in vivo. More recent
in vivo studies involving the infusion of MPO into mice demonstrated reduced macrophage-to-feces reverse cholesterol transport
(50), also strongly supporting a possible (patho)physiologic association between APOA1 and MPO in vivo. Additionally, this result
might also indicate a negative effect of MPO on PON1 activity
in part through interaction with HDL as a trimeric MPO-PON1HDL complex. Since PON1 has been suggested to help promote
some of the cholesterol efflux activity of HDL (56–58), the present demonstrations of MPO-dependent oxidative modification
and inactivation of PON1 in vitro and in vivo may be considered
an alternative mechanism for generating a “dysfunctional HDL”
particle (or perhaps more precisely, a “dysfunctional HDL-associated proteome”) during inflammation. It is of interest that a
recently published study examining systemic MPO activity and
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various HDL-related activities, including cholesterol efflux activity, antioxidant function, and PON1 activity, among subjects with
rheumatoid arthritis noted that higher plasma MPO activity was
associated with worse HDL functional measures (59). In summary,
HDL appears to serve as the scaffolding upon which functionally
related proteins can assemble and interact, serving as a mechanism
to “fine tune” biological functions. The evidence provided herein
reveals the existence of an HDL-MPO-PON1 ternary complex in
which each partner in the complex functions to reciprocally modulate the other’s activity, influencing oxidant stress and lipid peroxidation during inflammation. The demonstration that these
proteins form a functional ternary complex, the identification of
key residues supporting these interactions, and the demonstration
that these residues may be targeted for oxidative modification and
inactivation during inflammation provide a structural basis that
may partially help explain many of the observations reported in
both past and the present studies at the cellular, animal model,
and human clinical investigation levels. Given the complexity and
heterogeneity of the associated proteins observed in HDL, a vast
number of distinct functional clusters of proteins on distinct HDL
assemblies likely exist (60), further adding to the functional complexities of this multifaceted lipoprotein.
Methods
Materials
L-[13C6]tyrosine and L-[13C9,15N1]tyrosine were purchased from Cambridge
Isotope Laboratories. RAW264.7 cells were obtained from ATCC. [3H]Cholesterol was obtained from Amersham Biosciences. Human MPO was isolated and characterized as described (29). All other reagents were obtained
from Sigma-Aldrich unless otherwise specified.

General procedures
Protein content was determined by the Markwell-modified Lowry protein
assay (61) with BSA as a standard. The concentration of H2O2 was determined spectrophotometrically (ε240 = 39.4 M–1 •cm–1), and the concentration
of NaOCl was determined spectrophotometrically (ε292=350 M–1 •cm–1).
LDL and HDL were isolated by sequential ultracentrifugation (62). The
plasmid (G3C9) for generating recombinant PON1 was provided by Dan
S. Tawfik (The Weizmann Institute of Science, Rehovot, Israel) and purified as described (63). Protein-bound ClTyr was quantified as described
by stable isotope dilution LC/MS/MS analyses using synthetic 3-Cl-[13C6]
tyrosine and L-[13C9,15N1]tyrosine as internal standards on an ABI SCIEX
QTRAP 5500 mass spectrometer (23, 31). PON1 activity was measured
using a paraoxon substrate on an open channel of an Architect ci8200
platform (Abbott Diagnostics), and the rate of generation of paranitrophenol was determined at 405 nm using an extinction coefficient of 17,000
M–1 •cm–1 (21, 22). Activity was determined in reaction mixtures composed
of 1.5 mM paraoxon, 10 mM Tris HCl (pH 8.0), 1 M sodium chloride, and
2 mM calcium chloride at 24°C. Results were expressed as micromoles of
paranitrophenol produced per minute per milliliter of serum. Peroxidase
activity was measured spectrophotometrically at 650 nm by using a TMB
substrate. Cholesterol efflux (ABCA1-dependent and total) activity of
APOA1 and nHDL were determined as described (23).

Clinical specimens
Two clinical case-control cohorts of ACS subjects were enrolled for these
studies. The first was comprised of subjects (n = 26) presenting for diagnostic
coronary angiography at the time of ACS and healthy nondiabetic control
subjects (n = 26; age-, sex-, and blood pressure–matched) presenting to a pre-

ventive cardiology clinic for risk factor evaluation and recommendations.
An independent cohort of ACS subjects (n = 10) were enrolled from the Cardiovascular Center, University Hospital Zurich at the time of presentation,
along with 10 healthy volunteers (age-, sex-, and blood pressure–matched
controls) responding to advertisements. HDL particles were isolated by
buoyant density centrifugation from atherosclerotic lesions found in arterial
tissues obtained at the time of vascular surgery. All tissues were immediately
rinsed in ice-cold PBS supplemented with 2 mM diethylenetriaminepentaacetic acid (DTPA) and immediately snap frozen in buffer (65 mM sodium
phosphate [pH 7.4], 2 mM DTPA, and 100 μM butylated hydroxytoluene)
with liquid N2 and stored under argon at –80°C until analysis.

Mouse models of inflammation
Age- and sex-matched C57BL/6J PON1 KO (19), human PON1 Tg (20)
(>10 generations backcrossed onto a C57BL/6J background) and C57BL/6J
WT mice were used for acute peritonitis studies. Animals were injected i.p.
with 1 ml of 4% thioglycollate broth. Twenty hours after recruitment, the
mice were injected with zymosan (250 mg/kg) (34). Peritoneal lavage was
performed 4 hours later with PBS containing 100 μM butylated hydroxytoluene and 100 μM DTPA, aliquoted into cryovials, and overlaid with
argon, immediately flash frozen in liquid nitrogen, and stored at –80°C
until analysis. Age- and sex-matched C57BL/6J MPO KO (>10 generations
backcrossed onto C57Blk/6J), C57Blk/6J human MPO Tg mice, and WT
mice were used for subacute peritonitis studies. Zymosan was suspended
in sterile PBS to a final concentration of 7 mg/ml and injected i.p. at a final
dose of 100 mg/kg. Seventy-two hours later, blood was drawn from the
mice. The control animals received i.p. injections of PBS.

Mass spectrometry of neutrophil- and MPO-generated oxidation
products of arachidonic acid and linoleic acid
Human PMNs were isolated from whole blood obtained from healthy and
MPO-deficient subjects as described (33) and used immediately for experiments. PMNs (106/ml) were incubated at 37°C with 50% (v/v) human
serum under air in phenol red–free HBSS supplemented with 100 μM
DTPA, activated where indicated in Figure 1D and Figure 1E by adding
200 nM phorbol myristate acetate (PMA), and maintained in suspension by gentle mixing every 5 minutes. After 2 hours, the reactions were
stopped by immersion in an ice/water bath, followed by centrifugation
at 4°C and the immediate addition of 50 μM butylated hydroxytoluene
and 300 nM catalase to the supernatant. Lipid peroxidation products
in the supernatant were then rapidly assayed as described below. Reactions with isolated MPO were performed at 37°C in sodium phosphate
buffer (20 mM, pH 7.0) supplemented with 100 μM DTPA using 65 nM
MPO and 100 μM H2O2 final (added over at least 4 aliquots every 15
minutes). Reactions were terminated as described above for the PMN
studies. Deuterated internal standard, 12(S)-hydroxy-5,8,10,14-eicosatetraenoic-5,6,8,9,11,12,14,15-d8 acid (12-HETE-d8; Cayman Chemical Company) was added, lipids were extracted, and both precursors
(arachidonic and linoleic acids) and oxidized fatty acids were quantified
with stable isotope dilution LC/MS/MS using established methods on an
ABI SCIEX API 5000 triple quadrupole mass spectrometer (34).

Human APOA1 isolation and nHDL preparation
Human APOA1 was purified from isolated human HDL, and recombinant
mutant forms of human APOA1 were prepared, the His tag was removed,
and the forms were isolated as described (43). Reconstituted nHDL was
prepared using the modified sodium cholate dialysis method (64) at an
initial molar ratio of 100:10:1 of POPC/cholesterol/isolated APOA1. HDL
particles were further purified by gel filtration chromatography using a
Sephacryl S300 column (GE Healthcare).
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Synthesis and use of photocholesterol to label PON1 residues
Photocholesterol was synthesized by conversion of 6-keto-5α-cholestan3β-ol (Sigma-Aldrich) to 6-azi-5α-cholestan-3β-ol (65), and purity was
established by both NMR and mass spectrometric analyses. nHDL containing the photocholesterol probe was prepared as above, but included photocholesterol instead of cholesterol. Photocholesterol containing nHDL was
maintained under a foil wrapper in brown glass vials until use. Photolysis
was performed on the photo-HDL-PON1 complexes (molar ratio of 1:1) at
room temperature in the dark using a UV lamp at 350 nm. After delipidation of the photo-HDL-PON1 complex, photolabeled proteins were subjected to LC/MS/MS analysis using an LTQ-MS system (Thermo Fisher
Scientific) for the identification of photocholesterol-labeled peptides.

Proteomics analyses of PON1
Sample preparations and LC-ESI-MS/MS. HDL was precipitated by chloroform/methanol (2:1 vol/vol), reduced with DTT, alkylated with iodoacetamide, and digested with sequencing grade trypsin (Promega). Peptides
were analyzed on a hybrid LTQ Orbitrap mass spectrometer (Thermo
Fisher Scientific) interfaced with a nanoelectrospray ion source. Peptides
were separated on a reverse-phase column using an acetonitrile and water
solvent system containing 0.2% formic acid with a flow rate of 200 nl/
minute. Up to 5 data-dependent MS2 spectra of the most abundant doubly or triply charged precursor signals were acquired in the linear ion trap
using collision-induced dissociation. Peak lists were generated using either
Bioworks Browser 3.2 (Thermo Fisher Scientific) or Mascot Distiller software 2.3.2 (Matrix Science). The resulting Unified Search Files (*.srf) were
searched against the UniProt FASTA of APOA1 (P02647 [25-267]), while
Mascot Generic Files (*.mgf) were searched using the Mascot server v2.2
(1) against a human protein database downloaded from the European Bioinformatic Institute (EBI) (release date: 19/01/2010). Only strictly tryptic
peptides (66) with a maximum of 1 missed cleavage site were allowed in
the database searches. Monoisotopic precursor ions were searched with a
tolerance of 6 ppm, with 0.5 Da for the fragment ions in the data obtained
from the hybrid LTQ Orbitrap mass spectrometer. The signal tolerance for
the ion trap mass spectrometer was 1.0 Da for the precursor ion and 0.5 Da
for the fragment ions. Unidentified fragment ions in all fragmentation
spectra were manually validated using Protein Prospector (University of
California) (67, 68). H/D exchange and tandem mass spectrometric studies
were performed as described previously (23, 43).
Quantification of oxidized paraoxonase peptides. Two PON1 peptides (IFFY
DSENPPASEVLR; VVAEGFDFANGINISPDGK) that were not modified
and readily observable were selected as reference peptides, and extracted
ion chromatograms were obtained from these peptides. Extracted ion
chromatograms were also obtained from modified peptides containing
methionine oxidation and their corresponding unmodified parent peptides. The chromatographic peak area ratio was calculated as the peak
area of oxidized or parent unmodified peptide divided by the peak area of
the reference peptide.
Effect of methionine sulfoxide reductase on PON1 activity. HDL was incubated
with the MPO/H2O2/Cl system at a molar ratio of H2O2/APOA1 (50:1,
mol/mol) at 37°C for 1 hour in 10 mM sodium phosphate buffer (pH 7.4)
containing 100 M DTPA. For the MPO-H2O2Cl system, the reaction mixture was supplemented with 50 nM MPO, 100 mM NaCl, and 250 μM
H2O2. Oxidation was terminated by the addition of 5 mM methionine. For
the reduction reaction, oxidized HDL (5 μM APOA1) was incubated with
1 μM methionine sulfoxide reductase (MsrA) and 1 μM MsrB (both from
Jena Bioscience) for 2 hours at 37°C in Tris-HCl buffer (25 mM, pH 7.4)
containing 15 mM dithiothreitol. Paraoxonase activity for the MsrA study
was measured by UV spectrophotometry in a 96-well plate format (Nunclon Surface) using paraoxon (Sigma-Aldrich) as a substrate. HDL (100 μg
3826

protein per well) was diluted in a reaction mixture containing 10 mM TrisHCl (pH 8.0), 1 M sodium chloride and 2 mM calcium chloride. The reaction was initiated at 24°C by the addition of 1.5 mM paraoxon. Data are
the mean ± SD of triplicate determinations.
Immunoprecipitation of HDL (APOA1), MPO, and PON1 in human plasma.
Human IgG was depleted from human plasma by a protein A column
(Pierce) initially to decrease nonspecific binding proteins. Human IgG–
depleted plasma (250 μl) spiked with isolated human MPO (60 μg) and
isolated human PON1 (60 μg) was precleared again using Pansorbin cells.
Precleared plasma (40 μl) was used for immunoprecipitation studies with
the indicated IgGs (mAb anti–human APOA1; G45615M; BIODESIGN
International); mouse mAb against human MPO (ab51065; Abcam), or
no antibody as a control. For endogenous PON1 immunoprecipitation,
2 milliliters of human IgG–depleted plasma spiked with 100 μg MPO was
precleared with Pansorbin cells. Rabbit mAb anti-PON1 (2835-1; Epitomics) was used to immunoprecipitate PON1.
Surface plasmon resonance. Measurements of apparent dissociation constants between nHDL, MPO, or PON1 were performed using a BIAcore
2000 SPR Biosensor (Biacore) following the methods of Jin et al. (69)
with modifications. Briefly, 8,000 resonance units of anti-APOA1 antibody (Biodesign) or 2,000 resonance units of MPO were immobilized on
a CM5 sensor chip. nHDL surfaces were generated by injection of 7 μM
nHDL over the anti-APOA1 antibody surface. The apparent dissociation
constants were obtained by fitting background-subtracted SPR binding
data to the 1:1 binding with a drifting baseline model using BIAevaluation
software, (version 4.0; Biacore).

Statistics
Statistical significance of differences was determined by a 2-tailed Student’s t-test or ANOVA where appropriate. Spearman’s rank correlation
coefficients were calculated to test the correlation between PON1 activity
and protein-bound 3-ClTyr levels. P values less than 0.05 were considered
statistically significant.

Study approval
All participants gave written informed consent, and the IRB of the Cleveland Clinic Foundation approved the study protocol. Clinical investigations were conducted in accordance with the Declaration of Helsinki principles. All animal studies were performed using approved protocols from
the Animal Research Committee of the Cleveland Clinic.
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